Related Experiment Video
Updated: Mar 6, 2026
08:49
Models of Bone Metastasis
Published on: September 4, 2012
43.3K
MIC1/GDF15 as a Bone Metastatic Disease Biomarker
Jindra Windrichova1, Radka Fuchsova1, Radek Kucera2
1Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
Anticancer Research
|March 19, 2017
Summary
Growth Differentiation Factor 15 (MIC1/GDF15) shows promise as a biomarker for detecting bone metastases in cancer patients. Higher levels were observed in patients with bone metastases, indicating its potential for monitoring disease occurrence.
Area of Science:
- Oncology
- Biomarker Discovery
- Cancer Metastasis
Background:
- Bone metastases are a common complication in various cancers, including prostate, breast, lung, and colorectal cancer.
- Accurate monitoring of bone metastases occurrence is crucial for effective patient management and treatment strategies.
Purpose of the Study:
- To evaluate MIC1/GDF15 as a potential biomarker for monitoring the occurrence of bone metastases.
- To assess the diagnostic performance of MIC1/GDF15 in distinguishing patients with and without bone metastases.
Main Methods:
- A cohort of 55 patients without bone metastases (control group) and 75 patients with bone metastases were analyzed.
- MIC1/GDF15 levels were measured and compared between the two groups.
- Receiver operating characteristic (ROC) analysis was performed to determine the biomarker's efficacy.
Main Results:
- Significantly higher levels of MIC1/GDF15 were found in patients with bone metastases compared to the control group (p<0.0001).
- ROC analysis demonstrated a strong diagnostic performance with an Area Under the Curve (AUC) of 0.87.
- A cut-off value of 1.48 ng/ml achieved 65% sensitivity at 90% specificity.
Conclusions:
- Circulating MIC1/GDF15 is identified as a powerful biomarker for detecting bone metastatic disease.
- While promising, the sensitivity of MIC1/GDF15 alone may be insufficient, suggesting the need for further studies combining it with other biomarkers.
